Latest News

See All Latest News Right Pointing Arrow
Digital medical illustration of a bladder
Tools and Resources Drug Updates

Pharmacist's Application
to Practice: Nogapendekin
alfa inbakicept-pmln

August 27, 2024

Devan Parker, PharmD, PGY2 Oncology Pharmacy Resident and Juliana Leedy, PharmD, MS, Clinical Oncology Pharmacist, The University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama writes about nogapendekin alfa inbakicept-pmln.

LED sign that reads CAR T Cells
HOPA News Late Breaking News

Late-Breaking HOPA News: CAR-T Approval Updates

July 22, 2024

CAR-T approval updates show the treatment moving up the rung in Multiple Myeloma and breaking ground in Chronic Lymphocytic Leukemia

Early-Stage Non-small Cell Lung Cancer

Late-Breaking HOPA News: Adjuvant Alectinib in Early-Stage Non-small Cell Lung Cancer (NSCLC)

June 12, 2024

In April 2024, the FDA approved alectinib (Alecensa®) in patients with early-stage ALK-positive non-small cell lung cancer (NSCLC) based on the ALINA trial.

Pharmacist’s Application to Practice: Tislelizumab-jsgr

May 21, 2024

Kristine Pisikian, PharmD, PGY-1 Pharmacist Resident and Caroline Quinn, PharmD, BCOP, Specialty Clinical Program Director at Prime Therapeutics write about Tislelizumab-jsgr.

Advocacy

Pharmacists & Patients Lend Their Voices to Virtual Hill Day

May 07, 2024

HOPA members, patients, and caregivers participated in a total of 80 meetings with representatives from 31 states.

Metastatic Colorectal Cancer
Journal Club

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

May 04, 2024

The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously

Explore more from HOPA

-positive non-small cell lung cancer
Drug Updates

Pharmacist’s Application to Practice: Repotrectinib

January 25, 2024

Christopher L. Cornett II, PharmD PGY1 Acute Care Pharmacy Resident Anne E Hitron, PharmD, MS, MBA, BCOP ,Oncology Pharmacy Specialist, Baptist Health Louisville, Louisville, Kentucky

Metastatic Colorectal Cancer
Journal Club

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

May 04, 2024

The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously

Late Breaking News

Adapting Investigational Drug Services During a Pandemic

October 06, 2022

Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group

uveal melanoma with unresectable hepatic metastases
Drug Updates

Pharmacist’s Application to Practice: Hepzato Kit™

January 11, 2024

Lainey Vargo, PharmD, PGY2-Oncology Resident Katie Murto, PharmD, BCOP and Crystal Heise, PharmD, BCOP WVUH Hospitals, Morgantown, West Virginia.

Female reproductive organs
Late Breaking News

Late-Breaking HOPA News: RUBY5 and NRG GY018/Keynote-868 Trial

June 26, 2023

The use of molecular classification within endometrial cancer has continued to evolve with the incorporation of biomarker-driven therapy .

Myelofibrosis with anemia
Drug Updates

Pharmacist's Application to Practice: Momelotinib

January 11, 2024

Diana Mansour, PharmD, BCOP, Clinical Pharmacy Specialist, Charles M Gallagher, PharmD, PGY2 Oncology Pharmacy Resident; Kelsea Seago, PharmD, BCOP, Clinical Pharmacy Specialist, allfrom WVUH Hospitals, write about Momelotinib.

metastatic non-small cell lung cancer
Journal Club

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 23, 2023

First-line treatment with osimertinib–chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC.

Journal Club

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

October 23, 2023

Amivantamab–chemotherapy improved PFS and intracranial PFS versus chemotherapy.